A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar-Reference-Cited by-同舟云学术

A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar

Published:2013-11-20 Issue:4 Volume:54 Page:453-461
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Stringer Frances¹,DeJongh Joost²³,Scott Graham⁴,Danhof Meindert²³

Affiliation:

1. Takeda Pharmaceutical Company; Osaka Japan

2. LAP&P Consultants BV; Leiden The Netherlands

3. Leiden-Amsterdam Centre for Drug Research; Division of Pharmacology; Leiden The Netherlands

4. Takeda Global Research & Development; London UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcph.227/fullpdf

Reference34 articles.

1. An unusual metabolic pathway of sipoglitazar, a novel anti-diabetic agent: cytochrome P450-catalyzed oxidation of sipoglitazar acyl glucuronide;Nishihara;Drug Metab Dispos.,2011

2. Evaluation of the impact of UGT polymorphism on the pharmacokinetics and pharmacodynamics of the novel PPAR agonist sipoglitazar;Stringer;J Clin Pharmacol.,2013

3. The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agent;Stringer;Eur J Clin Pharmacol.,2013

4. Type 2 diabetes mellitus-a multifactorial disease;Hansen;Ann Univ Mariae Curie Sklodowska Med.,2002

5. Sulfonylurea inadequacy:efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57);Wright;Diabetes Care.,2002

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The structural basis of conserved residue variant effect on enzyme activity of UGT2B15;Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics;2023-05

2. High Throughput Study for Molecular Mechanism of Metformin Pre-Diabetic Protection via Microarray Approach;Endocrine, Metabolic & Immune Disorders - Drug Targets;2022-01

3. Efficacy of DPP‐4 inhibitors, GLP‐1 analogues, and SGLT2 inhibitors as add‐ons to metformin monotherapy in T2DM patients: a model‐based meta‐analysis;British Journal of Clinical Pharmacology;2018-12-06

4. Comparison of Power, Prognosis, and Extrapolation Properties of Four Population Pharmacodynamic Models of HbA1c for Type 2 Diabetes;CPT: Pharmacometrics & Systems Pharmacology;2018-03-25

5. Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs;The Pharmacogenomics Journal;2016-07-19